{"id":"tak-536tch","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL3348923","moleculeType":"Small molecule","molecularWeight":"506.30"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SGLT2 inhibitors like TAK-536TCH work by blocking the reabsorption of glucose in the kidneys, leading to reduced blood glucose levels. This can be beneficial for patients with type 2 diabetes. By inhibiting SGLT2, TAK-536TCH aims to improve glycemic control and potentially reduce cardiovascular risk.","oneSentence":"TAK-536TCH is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:17.184Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02277691","phase":"PHASE3","title":"A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-11-07","conditions":"Essential Hypertension","enrollment":341},{"nctId":"NCT02348658","phase":"PHASE1","title":"A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-01","conditions":"Hypertension","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAK-536TCH","genericName":"TAK-536TCH","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAK-536TCH is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}